Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
43.36
-1.98 (-4.37%)
Jan 28, 2026, 4:00 PM EST - Market closed
Maze Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Maze Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $42.29, which forecasts a -2.47% decrease in the stock price over the next year. The lowest target is $28 and the highest is $60.
Price Target: $42.29 (-2.47%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Maze Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $37 → $46 | Strong Buy | Maintains | $37 → $46 | +6.09% | Jan 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $55 | Buy | Initiates | $55 | +26.85% | Dec 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $60 | Strong Buy | Maintains | $50 → $60 | +38.38% | Dec 3, 2025 |
| Wedbush | Wedbush | Buy Maintains $35 → $36 | Buy | Maintains | $35 → $36 | -16.97% | Nov 7, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $27 → $37 | Buy | Maintains | $27 → $37 | -14.67% | Sep 29, 2025 |
Financial Forecast
Revenue This Year
n/a
from 167.50M
Revenue Next Year
1.36M
EPS This Year
-3.25
from 1.25
EPS Next Year
-3.21
from -3.25
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | 12.6M | ||||
| Avg | n/a | 1.4M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.21 | -2.88 | ||||
| Avg | -3.25 | -3.21 | ||||
| Low | -3.28 | -3.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.